Biomarker Analyses in Hepatocellular Carcinoma (HCC) Patients Treated With TheraSphere®

Stopped early

Conditions studied: Hepatocellular Carcinoma

In brief

To analyze specific angiogenic, inflammatory and immune profiles in hepatocellular carcinoma patients who undergo radioembolization.

Key facts

Study ID

NCT03203837

Run by

Northwestern University

People needed

4

Starts

2017-07-05

Expected to finish

2020-01-06

Last updated by the study team

2020-09-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Must have the diagnosis of HCC (biopsy or imaging criteria)
• Must have planned lobar TheraSphere treatment
• Must be able to give consent
• Must have an ECOG (Eastern Cooperative Oncology Group) performance status of ≤ 2
• Must have a life expectancy of ≥ 3 months
• Women must not be pregnant with an acceptable contraception in premenopausal women
• Must be > 4 weeks since prior radiation
• Must be > 2 weeks since liver surgery
• Must be ≥ 2 weeks post radiosensitizing chemotherapy or > 6 weeks since prior BCNU (carmustine) or Mitomycin-C

You may not qualify if…

• Patients are excluded if they do not meet the inclusion criteria

Where it is running

• Northwestern University — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.